Multiple reports suggest a solid standing for
Thermo Fisher Scientific (TMO) in the bio-tech market. Despite a cut in price target by
Bank of America analysts, the firm’s position is viewed as attractively valued and near the bottom, suggesting a potential for profit. TMO has demonstrated
renewed growth momentum post-pandemic and recently completed a $1B share repurchase, signaling a robust future through a $3B authorization. Elevated positions by Franklin Resources Inc., the Retirement Systems of Alabama, and Sanctuary Advisors LLC indicate the health of TMO's stock. TMO's investment in innovation is evidenced by the introduction of a ground-breaking mass spectrometer, advancing clinical research. Notable mentions include a massive $4B share buyback program, utilizing Next-Generation Sequencing Technology to propel myeloid cancer clinical research and treatment, and a sturdy Q3 2024 financial performance. Bullish signals reiterate the confidence in TMO's potential, albeit its dip in revenue figures. Investors who bet on TMO five years ago have seen returns of up to 113%. The company is among Morgan Stanley's high conviction stocks, reflecting Wall Street's bullishness.
Thermo Fisher Scientific TMO News Analytics from Wed, 24 Apr 2024 07:00:00 GMT to Sat, 14 Dec 2024 16:44:46 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -3
